Ikonisys: The Ikoniscope20 Preliminary Results Obtained With University of Connecticut School of Medicine (neag Cancer Center of UConn) in Detecting Rare Cells Surpass the Standards of Test in Immuno-oncology
16 Février 2022 - 6:42PM
Business Wire
- The Ikoniscope20 performs immune monitoring functions
more effectively, easily and competitively than conventional
flow cytometers (the standard tool used for such
detection)
- The Ikoniscope20 detects rare cells at a superior
rate to that provided by flow cytometers, also providing detailed
morphology information thanks to its high-quality images
- Monitoring of immune responses in cancer patients is an
increasing need because of newly approved immunotherapy
treatments
- Those results pave the way for new opportunities for
commercialization of the Ikoniscope20, as a better alternative than
the flow cytometer
Regulatory News;
Ikonisys SA (Code ISIN: FR00140048X2 / Mnemonique:
ALIKO), a company specializing in the early and accurate
detection of cancer with a unique fully-automated solution for
medical diagnostic labs, announced preliminary results of the
sensitivity of the Ikoniscope20 to detect rare cells carried out in
collaboration with the Carole and Ray Neag Comprehensive Cancer
Center of the University of Connecticut (UConn) School of
Medicine.
The Ikoniscope20 can detect as many as one positive cell among
each 250 tested cells from mice immunized with ovalbumin (protein
found in chick eggs). This frequency of detection is comparable or
higher than that obtained by flow cytometry (the standard tool used
for such detection).
Moreover, the Ikoniscope20 was able to detect as few as 1
positive cell among each 1,000 tested cells from un-immunized mice
(specific T cell is expected to be even lower than in immunized
mice). In contrast, standard flow cytometry could not detect them
at all.
The Ikoniscope20 can compete with more costly flow cytometry
instruments, and perform immune monitoring functions more
effectively, inexpensively and easily.
Thus, it opens other commercialization opportunities of the
Ikoniscope20 as a tool used by research laboratories for immune
response monitoring. There is a fast-growing addressable market for
monitoring newly approved immunotherapy treatments for cancer
patients.
Pramod Srivastava PhD MD, Director of the Neag Cancer
Center: “The ability of the Ikoniscope20 to detect such rare
cells should have a broad potential for applications in monitoring
immune responses to cancers in experimental studies including
monitoring of human cancer immuno-oncology trials, and is very
exciting”.
Dr. Michael Kilpatrick, Chief Scientific Officer of
Ikonisys, added: “We are honored to be working with a leading
medical center to further demonstrate the potential of the
Ikoniscope20 platform in the detection and quantification of
specific populations of clinically relevant cells in
immuno-oncology. These results open a new market opportunity for
the Ikoniscope20 as an instrument of choice, for research
laboratories dedicated to immuno-oncology, in addition to being an
instrument of discovery in the field of circulating tumor
cells”.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220216006047/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024